Zithromax EV in Community-Acquired Pneumonia (CAP)
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pneumonia
Intervention: Azithromycin (Drug); Ampicillin/sulbactam (Drug)
Phase: Phase 4
Sponsored by: Pfizer
Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam
is consistent with current guidelines for the treatment of CAP. In fact the International
guidelines for the treatment of CAP in hospitalised patients suggests the use of a
combination between a b-lactam and a macrolide.
This trial will allow investigators to evaluate the efficacy of azithromycin plus
ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired
pneumonia. In addition, this trial will allow investigators to evaluate the safety and
toleration of combination therapy.
Official title: A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the clinical efficacy of intravenous (IV) azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams twice a day (BID) for 2 to 5 days
followed by oral azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams.
Secondary outcome: To evaluate the eradication of baseline pathogens of IV azithromycin plus IV ampicillin/sulbactam followed by oral azithromycin plus IV ampicillin/sulbactam at Visit 3 and Visit 4
Minimum age: 18 Years.
Maximum age: N/A.
- Subjects must require hospitalization and intravenous therapy.
- Subjects must have a Fine pneumonia score > 70 (Fine Class > II).
- Subjects must have a medical history and clinical and radiological findings
consistent with a community-acquired bronchopneumonia or lobar pneumonia. The
following criteria must be met:
- new infiltrate(s) on chest X-ray; AND
- at least two of the CAP signs or symptoms.
- Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the
baseline visit, or treatment for more than 7 days within 15 days.
- Specific systemic diseases or other medical conditions that would interfere with the
evaluation of the therapeutic response or safety of the study drug, including:
- Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis
- Cavitary lung disease by chest X-ray;
- Primary lung cancer or other malignancy metastatic to the lung;
- Aspiration pneumonia;
- Known or suspected tuberculosis;
- Neoplastic disease;
- Cystic fibrosis;
- A history of any form of epilepsy or seizure;
- Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia
(this does not exclude patients with chronic obstructive pulmonary disease);
- Significant gastrointestinal or other conditions which may affect study drug
- Significant cardiovascular disorders.
- Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant
- Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT
(SGPT) greater than three times the laboratory upper limit of normal, or total
bilirubin greater than two times the upper limit of normal.
- Subjects already hospitalized or who resided in a long-term-care facility for greater
than 14 days before the onset of symptoms.
Locations and Contacts
Starting date: November 2003
Last updated: April 20, 2011